AR003414A1 - Uso de derivados de imidazol [1,2-a]piridina -3-acetamida y una composicion farmaceutica que comprende tal derivado - Google Patents

Uso de derivados de imidazol [1,2-a]piridina -3-acetamida y una composicion farmaceutica que comprende tal derivado

Info

Publication number
AR003414A1
AR003414A1 ARP960102094A AR10209496A AR003414A1 AR 003414 A1 AR003414 A1 AR 003414A1 AR P960102094 A ARP960102094 A AR P960102094A AR 10209496 A AR10209496 A AR 10209496A AR 003414 A1 AR003414 A1 AR 003414A1
Authority
AR
Argentina
Prior art keywords
group
hydrogen
derivative
pharmaceutical composition
halogen atom
Prior art date
Application number
ARP960102094A
Other languages
English (en)
Original Assignee
Clarendon Trading E Investimentos Lda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clarendon Trading E Investimentos Lda filed Critical Clarendon Trading E Investimentos Lda
Publication of AR003414A1 publication Critical patent/AR003414A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Dichos derivados responden a la fórmula general (I), en donde: Y representa un átomo de hidrógeno o halógeno o un grupo alquilo C1-4; A representa unradical naftilo o un radical (II) en donde cada uno de X1 y X2 independientementeen tre sí es un átomo de hidrógeno o halógeno, un grupoalcoxi C1-4, un grupo alquilo C1-6 ó CF3, CH3S-, CH3SO2- ó -NO2, y cada uno de R1 y R2 independientemente entre sí representa o bien un átomo de hidrógeno,o un grupo alquilo C1-5 recto oramific ado que no está substituido o que está substituido por uno o más átomos de halógeno,grupos hidroxilo,-N(C1-4 alquilo)2, carbamoilo o alcoxi C1-4, o un grupo alilo, o un grupo propargilo, o un grupo cicloalquilo C3-6, o un grupobencilo, o un grupo fenilo, no siendosambos R1 y R2 hidrógeno, o -NR1R2 representa un anillo heterocíclico que contiene de 3 a 6 átomos de carbono, o un anillo heterocíclico de la fórmula(III), en donde X es O, S, CHOR ó N-R, siendo Rhidrógeno o bencilo y siendo R hidrógeno, un grupo alquilo C1-4, o fenilo que no está substituido o queestá substituido por metoxi o un átomo de halógeno. Además, la invención se refiere a una composición farmacéutica que comprende talderivado.
ARP960102094A 1995-04-07 1996-04-08 Uso de derivados de imidazol [1,2-a]piridina -3-acetamida y una composicion farmaceutica que comprende tal derivado AR003414A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95RM000223A IT1276522B1 (it) 1995-04-07 1995-04-07 Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei

Publications (1)

Publication Number Publication Date
AR003414A1 true AR003414A1 (es) 1998-08-05

Family

ID=11403250

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102094A AR003414A1 (es) 1995-04-07 1996-04-08 Uso de derivados de imidazol [1,2-a]piridina -3-acetamida y una composicion farmaceutica que comprende tal derivado

Country Status (25)

Country Link
US (1) US5891891A (es)
EP (1) EP0819002B1 (es)
JP (1) JP4049390B2 (es)
KR (1) KR100425628B1 (es)
CN (1) CN1198612C (es)
AR (1) AR003414A1 (es)
AT (1) ATE222763T1 (es)
AU (1) AU707759B2 (es)
CA (1) CA2217590C (es)
CZ (1) CZ292020B6 (es)
DE (1) DE69623271T2 (es)
DK (1) DK0819002T3 (es)
EA (1) EA000396B1 (es)
ES (1) ES2182967T3 (es)
HU (1) HUP9900733A3 (es)
IL (1) IL117824A (es)
IT (1) IT1276522B1 (es)
MX (1) MX9707712A (es)
NO (1) NO315408B1 (es)
NZ (1) NZ304107A (es)
PL (1) PL322647A1 (es)
PT (1) PT819002E (es)
TW (1) TW450816B (es)
WO (1) WO1996031210A1 (es)
ZA (1) ZA962711B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US6333345B1 (en) 1999-05-14 2001-12-25 Sepracor, Inc. Methods of using and compositions comprising N-desmethylzolpidem
US6399621B1 (en) 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US20030091632A1 (en) * 1999-08-26 2003-05-15 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US6384221B1 (en) * 1999-09-02 2002-05-07 Neurocrine Biosciences, Inc. Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
WO2001078725A2 (en) * 2000-04-13 2001-10-25 Synthon B.V. Modified release formulations containing a hypnotic agent
DE60125429T2 (de) * 2000-04-24 2007-09-27 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartrat solvat
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10117183A1 (de) * 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
GB0311457D0 (en) * 2003-05-19 2003-06-25 Sciencom Ltd New therapeutic use
EP1624867A1 (en) * 2003-05-19 2006-02-15 Sciencom Ltd Further therapeutic use of zolpidem
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DK1691811T3 (da) 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
ES2337700T3 (es) 2004-02-18 2010-04-28 Sepracor, Inc. Terapia combinada de agonista de dopamina con sedantes para mejorar la calidad del sueño.
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
CA2629740A1 (en) * 2005-11-18 2007-06-14 Synthon B.V. Zolpidem tablets
GB2443928A (en) * 2006-11-08 2008-05-21 Regen Therapeutics Plc Transdermal pharmaceutical composition comprising Zolpidem
GB0809936D0 (en) * 2008-05-30 2008-07-09 Regen Therapeutics Plc Therapeutic use of zolpidem
WO2017214442A1 (en) 2016-06-08 2017-12-14 President And Fellows Of Harvard College Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome
WO2019232046A1 (en) 2018-05-29 2019-12-05 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
WO2020198275A1 (en) 2019-03-25 2020-10-01 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US5032595A (en) * 1989-11-24 1991-07-16 Fidia-Georgetown Institute For The Neurosciences Method of stimulating steroidogenesis with alpidem
US5206382A (en) * 1991-06-27 1993-04-27 Fidia Georgetown Institute For The Neurosciences Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders

Also Published As

Publication number Publication date
KR19980703707A (ko) 1998-12-05
NO315408B1 (no) 2003-09-01
IL117824A0 (en) 1996-08-04
ITRM950223A0 (it) 1995-04-07
PT819002E (pt) 2003-01-31
EP0819002A1 (en) 1998-01-21
ATE222763T1 (de) 2002-09-15
NZ304107A (en) 2000-12-22
HUP9900733A2 (hu) 1999-07-28
HUP9900733A3 (en) 2003-05-28
TW450816B (en) 2001-08-21
JP4049390B2 (ja) 2008-02-20
DK0819002T3 (da) 2003-01-06
NO974603L (no) 1997-11-24
DE69623271T2 (de) 2003-07-24
MX9707712A (es) 1998-03-31
CZ292020B6 (cs) 2003-07-16
DE69623271D1 (de) 2002-10-02
EP0819002B1 (en) 2002-08-28
KR100425628B1 (ko) 2004-06-23
NO974603D0 (no) 1997-10-06
PL322647A1 (en) 1998-02-16
CA2217590A1 (en) 1996-10-10
CZ316797A3 (cs) 1998-05-13
CN1183719A (zh) 1998-06-03
CA2217590C (en) 2008-08-12
AU5120096A (en) 1996-10-23
AU707759B2 (en) 1999-07-22
IL117824A (en) 2000-08-31
IT1276522B1 (it) 1997-10-31
EA000396B1 (ru) 1999-06-24
ITRM950223A1 (it) 1996-10-07
JPH11503149A (ja) 1999-03-23
ZA962711B (en) 1996-07-30
WO1996031210A1 (en) 1996-10-10
US5891891A (en) 1999-04-06
CN1198612C (zh) 2005-04-27
EA199700308A1 (ru) 1998-04-30
ES2182967T3 (es) 2003-03-16

Similar Documents

Publication Publication Date Title
AR003414A1 (es) Uso de derivados de imidazol [1,2-a]piridina -3-acetamida y una composicion farmaceutica que comprende tal derivado
DK0783500T3 (da) Aminoheterocykliske derivater som antithrombotiske eller antikoagulerende midler
ES2188194T3 (es) 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4.
AR058967A2 (es) Derivados de triazolo[4,5-d] pirimidina composiciones farmaceuticas que los contienen y proceso de preparacion para dichos compuestos
ES2168953A1 (es) Derivados de oxima y su uso como acidos latentes
DK0861228T3 (da) Lipopolyaminer som transfektionsmidler samt deres farmaceutiske anvendelser
DK164701C (da) Thiazolidinderivater, deres fremstilling og midler, som indeholder dem
AR002012A1 (es) Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto.
DK57492A (da) Farmaceutiske praeparater af n-phenylbenzamidderivater
NO20022232L (no) Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII
ES2045485T3 (es) Metodo de preparacion de derivados de fenil-6 piperazinilalquil-3 1h, 3h-pirimidinediona-2,4, y su aplicacion en terapeutica.
FI824531L (fi) N-oxid-foereningar, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska preparat
MX9204179A (es) Derivados de imidazo(2,1-b)benzotiazola-3-acetamida, su preparacion y su aplicacion en terapeutica.
AU4083485A (en) Tetrahydrothienopyridines
DK0861250T3 (da) Amindin- og isothiourinstofderivater som inhibitorer for nitrogenmonoxidsyntase
DK0486385T3 (da) Imidazolderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
DK0736009T3 (da) N-oxider af 4-arylpiperaziner og 4-arylpiperidiner som antipsykotiske medikamenter
DK0906295T3 (da) Dibenzo-oxazepin- og -dioxepinderivater og deres anvendelse som anti-tumormidler
DE3161553D1 (en) Thiazolo(3,2-a)pyrimidine derivatives, their preparation and pharmaceutical compositions containing them
SE8603589D0 (sv) Metylendioxifenantren- och stilbenderivat
DK0782574T3 (da) Bicycliske carboxiamider som 5-HT1A-receptorligander
ES2096931T3 (es) Derivados de 4-oxa-1-azabiciclo(3,2,0)heptan-7-ona utilizados como agentes antitumorales.
GB2276619A (en) Cyclic ketal derivatives
DE68915484D1 (de) Sulfonylindolizinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Synthese-Zwischenprodukte.
DK163922C (da) 2,3-dihydro-3-phenyl-2-benzofuranonderivater, fremgangsmaader til deres fremstilling og farmaceutiske midler indeholdende dem

Legal Events

Date Code Title Description
FB Suspension of granting procedure